| Title |
Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress
|
|---|---|
| Published in |
Current Oncology Reports, October 2017
|
| DOI | 10.1007/s11912-017-0643-0 |
| Pubmed ID | |
| Authors |
Paola Jimenez, Claudio Tatsui, Aaron Jessop, Sonali Thosani, Camilo Jimenez |
| Abstract |
The purpose of this manuscript is to review the progress in the field of therapeutics for malignant pheochromocytomas and sympathetic paraganglioma (MPPG) over the past 5 years. The manuscript will describe the clinical predictors of survivorship and their influence on the first TNM staging classification for pheochromocytomas and sympathetic paragangliomas, the treatment of hormonal complications, and the rationale that supports the resection of the primary tumor and metastases in patients with otherwise incurable disease. Therapeutic options for patients with bone metastasis to the spine will be presented. The manuscript will also review chemotherapy and propose a maintenance regimen with dacarbazine for patients initially treated with cyclophosphamide, vincristine, and dacarbazine. Finally, the manuscript will review preliminary results of several phase 2 clinical trials of novel radiopharmaceutical agents and tyrosine kinase inhibitors. MPPGs are very rare neuroendocrine tumors. MPPGs are usually characterized by a large tumor burden, excessive secretion of catecholamines, and decreased overall survival. Recent discoveries have enhanced our knowledge of the pathogenesis and phenotypes of MPPG. This knowledge is leading to a better understanding of the indications and limitations of the currently available localized and systemic therapies as well as the development of phase 2 clinical trials for novel medications. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 57 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Doctoral Student | 11 | 19% |
| Student > Bachelor | 8 | 14% |
| Student > Ph. D. Student | 8 | 14% |
| Other | 7 | 12% |
| Researcher | 5 | 9% |
| Other | 10 | 18% |
| Unknown | 8 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 49% |
| Biochemistry, Genetics and Molecular Biology | 5 | 9% |
| Neuroscience | 3 | 5% |
| Economics, Econometrics and Finance | 2 | 4% |
| Agricultural and Biological Sciences | 2 | 4% |
| Other | 5 | 9% |
| Unknown | 12 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 December 2018.
All research outputs
#16,730,780
of 25,591,967 outputs
Outputs from Current Oncology Reports
#636
of 995 outputs
Outputs of similar age
#204,178
of 340,001 outputs
Outputs of similar age from Current Oncology Reports
#4
of 7 outputs
Altmetric has tracked 25,591,967 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 995 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 340,001 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.